SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves rate hike and signal for further tightening have driven debate over higher-for-longer interest rates, Treasury yields, and their impact on rate-sensitive small caps. Traders have largely turned bearish on IWMs technical weakness and downside risk, though some see oversold conditions and the post-Fed rebound as a potential bounce setup.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Anticipation of Helus Pharmas HLP003 Phase 3 APPROACH topline results, expected in Q4 2026 after enrollment finished ahead of schedule, is driving attention, alongside optimism about the new CEO and recent insider buying. Traders are broadly bullish on the programs Phase 2 profile and psychedelic-sector momentum, while others highlight the binary trial risk, potential dilution, cash-runway concerns, and profit-taking.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

A sharp selloff following Dutch Bros recent earnings and the failed Salad and Go acquisition has drawn attention, with traders debating whether the decline reflects valuation compression, high interest rates, weaker discretionary spending and competition. Bulls view the move as an oversold reaction and point to continued store expansion and revenue growth, while bears remain focused on the stocks elevated multiple, possible dilution and insider selling.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling allowing states to regulate Kalshi-style sports contracts as gambling is being viewed by traders as a potential win for DraftKings, reducing a key prediction-market competitive threat. The community remains divided, with some expecting traditional sportsbooks to benefit while others question the rulings scope, ongoing appeals, and DraftKings profitability and execution.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI (UX111), the first treatment for Sanfilippo syndrome type A, is driving attention, along with the Priority Review Voucher and planned commercial launch. Traders are mostly bullish on the added revenue and cash potential, while skeptics point to the ultra-rare, one-time treatment market, safety monitoring requirements and cash burn; others are debating why the share-price reaction has been relatively muted.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

Speculation that Volkswagen may reduce or divest its QuantumScape stake amid broader asset sales is driving attention, with traders debating whether it signals weaker confidence in the partnership or is primarily a balance-sheet decision. The discussion also centers on whether the PowerCo licensing relationship remains intact and whether QuantumScape can prove scalable Eagle Line production.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklos new at-the-market equity offering is driving attention, with traders focused on potential dilution alongside recent founder and executive share sales. Bears view the financing as shareholder-unfriendly and evidence of continued selling pressure, while bulls argue it strengthens funding for the companys long-term advanced-nuclear and AI data-center power strategy.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs Investor Day announcementsincluding a higher full-year outlook following the SkyWater acquisition, the Superion 256 platform, and a quantum-safe security agreementhave renewed interest in its manufacturing scale and commercialization roadmap. Traders are broadly bullish on the quantum-computing thesis, though others describe the move as a sell-the-news rally and question valuation, profitability, and whether the technical milestones can be delivered.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Barclays bullish reassessment, citing physician-survey support for Lifileucel and the upcoming IOV-LUN-202 non-small-cell lung cancer update, is fueling attention alongside expectations for revised guidance and continued Amtagvi commercial progress. Traders are broadly bullish and discuss short covering and further re-rating, though some attribute the sharp move and pullbacks to profit-taking, options positioning, and broader biotech volatility.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves proposed convertible-debt financing and new at-the-market share-sale program are driving attention, with traders focused on leverage, potential dilution, and managements timing. Some investors view the capital raise as necessary to fund expanding AI compute capacity and point to higher-priced contracts and growing customer commitments, while others expect continued pressure on the shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Feed

News

Sentiment

Fundamentals

Info

MPS News